February 15, 2018 / 11:29 AM / 8 days ago

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

Feb 15 (Reuters) - Acorda Therapeutics Inc:

* Q4 REVENUE $188.4 MILLION

* Q4 NON-GAAP EARNINGS PER SHARE $0.61

* Q4 GAAP LOSS PER SHARE $3.70

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

* RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2018 ARE EXPECTED TO BE $100 MILLION TO $110 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below